Nascent Biotech, Inc. (NBIO)

OTCMKTS: NBIO · Delayed Price · USD
0.140
+0.010 (7.69%)
Jan 27, 2023, 2:10 PM EST - Market closed
Market Cap 16.74M
Revenue (ttm) n/a
Net Income (ttm) -166,028
Shares Out 119.56M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 66,400
Open 0.128
Previous Close 0.130
Day's Range 0.128 - 0.143
52-Week Range 0.040 - 0.452
Beta -3.07
Analysts n/a
Price Target n/a
Earnings Date n/a

About NBIO

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc.... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Sean Carrick
Country United States
Stock Exchange OTCMKTS
Ticker Symbol NBIO
Full Company Profile

Financial Performance

In 2022, NBIO's revenue was $1.00 million, an increase of 33.33% compared to the previous year's $750,000. Losses were -$470,390, -50.94% less than in 2021.

Financial Statements

News

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal...

2 days ago - Accesswire

Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial

NORTH PALM BEACH, FL / ACCESSWIRE / January 10, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the develo...

2 weeks ago - Accesswire

Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board

VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal anti...

1 month ago - Accesswire

Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394

VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company who develops monoclonal ant...

3 months ago - Accesswire

Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research

VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company focused on the development o...

4 months ago - Accesswire

Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

VERO BEACH, FL / ACCESSWIRE / September 13, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the developmen...

4 months ago - Accesswire

Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

VERO BEACH, FL / ACCESSWIRE / July 19, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of ...

6 months ago - Accesswire

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of m...

8 months ago - Accesswire

Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...

9 months ago - Accesswire

Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

VERO BEACH, FL / ACCESSWIRE / April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc ...

10 months ago - Accesswire

The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial

SAN DIEGO, CA / ACCESSWIRE / March 8, 2022 / Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational immunother...

11 months ago - Accesswire

Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

Milestone Payment is the Second of Four in $5M Pritumumab Licensing Deal VERO BEACH, FL / ACCESSWIRE / February 23, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Com...

1 year ago - Accesswire

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development ...

1 year ago - Accesswire

Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration

SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome di...

1 year ago - Accesswire

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of ...

1 year ago - Accesswire

Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mo...

1 year ago - Accesswire

Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab

TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Compan...

1 year ago - Accesswire

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of mon...

1 year ago - Accesswire

Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt

SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of ...

1 year ago - Accesswire

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of ...

1 year ago - Accesswire

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of ...

2 years ago - Accesswire

Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of m...

2 years ago - Accesswire

Nascent Biotech Gains On Encouraging Pritumumab Data From Preclinical Studies

Nascent Biotech Inc (OTCMKTS: NBIO) has announced the publication of promising in-vitro study results from its pritumumab (PTB) research collaboration with Syracuse University, validating the potentia...

2 years ago - Benzinga